31
Mar

Back in mid-January, CoLucid Pharmaceuticals raised about $37 million to back its Phase III study of a new migraine drug. A week ago the biotech said it had pulled up stakes in Durham, NC, and had temporarily located its HQ in Burlington, MA, as it searched for new offices in Cambridge. And now it has pulled back the covers on an $86 million IPO.

…read more

Source: On the road to Cambridge, migraine drug biotech CoLucid files for an $86M IPO

    

0 No comments